drugset
drugset / Trial / NCT00730171

An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

NCT00730171 ↗

Phase 3 Completed 1743 enrolled Ironwood Pharmaceuticals, Inc. Forest Laboratories · collab
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).

Timeline

Start
2008-09
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Linaclotide Peptide 290 ug Oral

Indications

constipation disorder irritable bowel syndrome